香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 承董事會命 海吉亞醫療控股有限公司 主席 朱義文先生 Hygeia Healthcare Holdings Co., Limited （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） 海 吉 亞 醫 療 控 股 有 限 公 司 （股 份 代 號：6078） 董事會會議日期 海吉亞醫療控股有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此公佈， 董事會會議將於二零二五年八月二十八日（星期四）舉行，藉以（其中包括）考 慮及批准本公司及其附屬公司截至二零二五年六月三十日止六個月之中期業 績及其發佈，並考慮建議派發中期股息（如有）。 香港，二零二五年八月十八日 截至本公告日期，董事會包括主席兼執行董事朱義文先生；執行董事任愛先生、程歡歡女士、 張文山先生及姜蕙女士；以及獨立非執行董事葉長青先生、趙淳先生及張國忠先生。 ...

Group 1: Hong Kong Stocks - Ascentage Pharma-B (06855) opened over 5% higher after receiving FDA and EMA approval for its drug, Lisenglitazone, for high-risk MDS in Phase III clinical trials [1] - Haijia Medical (06078) fell over 5% following a profit warning, expecting a mid-term net profit decline of approximately 34% to 39% due to factors like centralized procurement and increased depreciation from new hospitals [1] - Hua Hong Semiconductor (01347) dropped over 6% as it announced plans to acquire a controlling stake in Shanghai Huali Microelectronics to address industry competition [1] - Zhonghui Biotech-B (02627) rose over 8% after receiving IND approval for its recombinant respiratory syncytial virus vaccine in both the US and China [1] - NetDragon (00777) surged over 10% after forming a strategic alliance with Zhongke Wenge to promote AI technologies abroad [1] - Great Wall Motors (02333) increased over 12% following the completion of its factory in Brazil, with an initial production capacity of 30,000 vehicles per year [1] - Yuewen Group (00772) rose over 20% as its first-half performance exceeded expectations, benefiting from growth in licensing business and steady performance of short dramas [1] Group 2: Other Notable Stocks - Huirui Group (00806) increased over 8% after reporting first-half results that met market expectations and is applying for MRF mutual recognition for other products [2] - Soundon Technology (02495) surged nearly 30% after announcing a projected net profit exceeding 50 million yuan for the first half, marking a turnaround from losses [2] - Robotics concept stocks saw significant gains, with Jinshang Machine Tool (01651) up over 11% and Lijin Technology (00558) up over 3% [2] Group 3: US Stocks - Intel (INTC.US) rose 2.93% amid reports of negotiations with the Trump administration for government investment to support domestic manufacturing [3] - Hesai Technology (HSAI.US) increased 9.73% after reporting over 50% year-on-year revenue growth for Q2 2025 [3] - UnitedHealth (UNH.US) surged 11.98% following Berkshire Hathaway's new investments in the company [3] - NIO (NIO.N) rose 8.09% as it announced the upcoming launch of its new ES8 model [4] - Xunlei (XNET.US) continued to rise by 26.53% after reporting a 30.6% year-on-year revenue increase for Q2 2025 [5]

本文源自：金融界AI电报 海吉亚医疗(06078.HK)发布公告，截至2025年6月30日止六个月，预计：公司收入较去年同期下降约 15%至17%;净利润较去年同期下降约34%至39%;非国际财务报告准则经调整净利润1较去年同期下降约 32%至37%;及经营活动所得现金净额较去年同期提升约28%至32%。 ...

Group 1 - The company expects a revenue decline of approximately 15% to 17% and a net profit decline of about 34% to 39% for the six months ending June 30, 2025 compared to the same period last year [1] - The decrease in revenue and net profit is primarily due to industry impacts such as centralized procurement, DRG payment reform, macroeconomic influences, and increased depreciation from newly opened hospitals [1] - The company anticipates a decrease in trade receivables by approximately 10% to 11% and a reduction in total liabilities by about 4.5% to 5.5% as of June 30, 2025 [1] Group 2 - The company aims to enhance service processes to meet diverse health needs and improve patient satisfaction while maintaining a focus on operational efficiency and shareholder returns [2] - The company expresses confidence in the long-term development prospects of the industry and itself [2] - Capital expenditures are expected to decline by approximately 28% to 29% compared to the same period last year, while free cash flow is projected to significantly improve [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Hygeia Healthcare Holdings Co., Limited （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） 海 吉 亞 醫 療 控 股 有 限 公 司 （股 份 代 號：6078） 盈利預警 海吉亞醫療控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據香 港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法例第571 章《證券及期貨條例》第XIVA部項下之內幕消息條文（定義見上市規則）作出本 公告。 本公司董事會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資者，基於 對本集團截至2025年6月30日止六個月未經審核綜合管理賬目（按國際財務報告 準則(IFRS)編製）的初步評估及董事會目前可得資料，預計： 1 本集團將「非國際財務報告準則經調整淨利潤」定義為經扣除(i)股份支付薪酬開支；(ii) 收購醫院資產評估增值所產生的折舊及攤銷 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 截至月份: 2025年7月31日 狀態: 新提交 公司名稱: 海吉亞醫療控股有限公司 本月底法定/註冊股本總額： USD 50,000 備註： 本公司為於開曼群島註冊成立的有限公司。 FF301 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 第 1 頁 共 10 頁 v 1.1.1 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06078 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | ...

Group 1: Market Performance - The Hong Kong stock market saw all three major indices decline in the morning session, with the Hang Seng Tech Index dropping 1.57%, marking a five-day losing streak [1] - The Hang Seng Index and the Hang Seng China Enterprises Index both fell by 0.43% [1] - Internet healthcare stocks performed strongly, with Ping An Good Doctor surging 9% to reach a new high [1] Group 2: ETF Performance - The Hang Seng Medical ETF (513060) experienced significant fluctuations, rising over 3% during the session with a trading volume nearing 2.5 billion yuan and a turnover rate exceeding 30% [1] - Most constituent stocks within the ETF saw gains, including Ping An Good Doctor up over 11%, MicroPort Medical up over 8%, and several others with gains exceeding 4% [1] Group 3: Policy Developments - The National Healthcare Security Administration (NHSA) held four seminars in July 2025 to discuss a comprehensive policy support system for innovative drugs and medical devices [2][3] - The first seminar focused on establishing a scientific value evaluation system for innovative products, which is expected to enhance the efficiency of healthcare resource allocation [2] - Subsequent seminars addressed collaborative innovation among various stakeholders, the empowerment of research and development through healthcare data, and the identification of pain points in drug development [3] Group 4: Policy Implementation - Recent procurement policy optimizations by the NHSA have improved market access for innovative drugs and medical devices, allowing medical institutions to report quantities by brand and ensuring fair competition [4] - A new pricing mechanism for newly listed drugs has been established, allowing innovative drugs with breakthrough efficacy to secure reasonable premium pricing [4] Group 5: Industry Trends - The policy changes are reshaping the pharmaceutical industry's innovation logic, encouraging differentiation in innovation and directing capital towards unmet clinical needs [5] - The internationalization of Chinese innovative drugs is accelerating, with significant increases in licensing transactions and overseas revenue for companies like BeiGene and Innovent Biologics [5] - The ability to leverage healthcare data for post-market research is becoming a competitive advantage for companies [5] Group 6: High-End Medical Equipment - The government is supporting the development of high-end medical devices, setting a target for 70% of county-level hospitals to use domestically produced equipment by 2025 [6] - The new medical infrastructure is expected to drive over 200 billion yuan in equipment procurement demand [6] Group 7: Investment Opportunities - The Hang Seng Medical ETF (513060) is positioned to benefit from the policy dividends and industry upgrades, focusing on innovative drug and medical device companies [7] - The ETF's constituent companies are expected to experience significant growth as the government supports high-end medical equipment and innovative drug development [7][8]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [4]. Core Insights - The overall revenue scale continues to grow, with outpatient revenue increasing at a faster pace. The company's strength in comprehensive cancer treatment is continuously enhancing. In 2024, total revenue is projected to be 4.446 billion yuan, representing a year-on-year growth of 9.0%. The main hospital business revenue is expected to reach 4.322 billion yuan, up 11.1% year-on-year [3][4]. - The company is actively expanding its treatment projects, particularly in oncology, improving treatment methods, and enhancing management efficiency. By the end of 2024, the company completed 96,993 surgeries, a year-on-year increase of 15.8%, with surgical revenue growing by 21.2% [3]. - The report adjusts the net profit forecasts for 2025 and 2026 downwards due to unexpected impacts from uncollected medical insurance income and the company's self-built planning. The expected net profit for 2027 is projected at 891 million yuan, corresponding to a price-to-earnings (P/E) ratio of 12/11/9 times [4]. Financial Summary - In 2024, the company is expected to achieve total revenue of 4.446 billion yuan, with a year-on-year growth of 9.04%. The net profit attributable to the parent company is projected to be 598.26 million yuan, a decrease of 12.40% year-on-year [9]. - The company has been expanding its physician scale and increasing patient visits, with approximately 4.5 million visits in 2024, a year-on-year increase of 23.8% [9]. - The company's financial metrics indicate a projected EPS of 0.97 yuan for 2024, with a P/E ratio of 13.84 [10].

Financial Performance - Revenue for the year ended December 31, 2024, was RMB 4,446,120, an increase of 9.1% from RMB 4,076,680 in 2023[9] - Gross profit for 2024 was RMB 1,329,473, with a gross margin of 29.9%, down from 31.6% in 2023[9] - Net profit for 2024 was RMB 598,332, representing a decrease of 12.6% compared to RMB 684,948 in 2023, resulting in a net profit margin of 13.5%[9] - EBITDA for the year was RMB 1.11 billion, indicating steady growth and maintaining industry-leading operational efficiency[20] - The company’s hospital business revenue was RMB 4.32 billion, up 11.1% from the previous year, with outpatient service revenue increasing by 20.8%[21] - The company completed 96,993 surgeries during the year, a 15.8% increase compared to the previous year, with surgical revenue rising by 21.2%[22] - The company continues to expand its oncology-related business, with revenue increasing from RMB 1.78 billion to RMB 1.96 billion, a growth of 10.4%[23] - The group achieved a record revenue of RMB 4.45 billion for the fiscal year ending December 31, 2024, representing a 9.1% increase year-over-year[20] - The company's gross profit increased by 3.4% from RMB 1,286.3 million to RMB 1,329.5 million, with a gross margin of 29.9% for the year ending December 31, 2024[63] - The company’s total liabilities decreased by 5.0% to RMB 4.25 billion, reflecting effective cost management strategies[20] Assets and Liabilities - The total current assets as of December 31, 2024, were RMB 1,825,749, a decrease from RMB 1,975,590 in 2023[9] - The total non-current assets increased to RMB 9,103,506 in 2024 from RMB 8,758,973 in 2023[9] - Total assets increased by 1.8% from RMB 10,734.6 million as of December 31, 2023, to RMB 10,929.3 million as of December 31, 2024[81] - Trade receivables decreased by 4.7% from RMB 864.0 million as of December 31, 2023, to RMB 823.0 million as of December 31, 2024[83] - Trade payables decreased by 20.1% from RMB 687.1 million as of December 31, 2023, to RMB 549.0 million as of December 31, 2024[85] - Other payables decreased by 18.7% from RMB 723.0 million as of December 31, 2023, to RMB 587.5 million as of December 31, 2024[85] Operational Efficiency and Growth - The company operates 16 hospitals focused on oncology across 13 cities in 8 provinces in China, aiming to address the significant demand for cancer treatment in non-first-tier cities[11] - The company emphasizes a standardized management model to support both organic growth and acquisitions, enhancing operational efficiency[12] - The number of patient visits reached approximately 4.5 million, a year-over-year increase of 23.8%[20] - The group has a total of 7,607 medical professionals as of December 31, 2024, an increase of 124 from the previous year, including 1,236 senior title professionals[31] - The group has established a multidisciplinary collaboration for complex cases, enhancing the quality of medical services and patient care[35] Patient Care and Satisfaction - Patient satisfaction improved to 97.03%, an increase of 0.91 percentage points from the previous year[19] - The group achieved a patient satisfaction rate of 97.03% in 2024, an increase of 0.91 percentage points from 2023, with a goal of reaching 100% satisfaction[38] - The group’s internet hospital registered nearly 230,000 consultations during the reporting period, enhancing patient access to healthcare services[37] Technology and Innovation - The company is actively embracing AI technology in various medical applications to enhance operational efficiency and patient experience[19] - AI technology has improved the detection rate of small lung nodules by 10%-15% compared to traditional methods, and reduced chest CT report generation time by 50%-70%[39] - The company is actively embracing new technologies, including AI imaging recognition, to enhance diagnostic efficiency and patient experience[58] Strategic Initiatives - The company is actively pursuing a merger and acquisition strategy to capitalize on industry consolidation opportunities[15] - The company is focused on expanding its market presence and improving service capabilities in response to the government's health service capacity enhancement initiatives for 2024[52] - The company is exploring strategic acquisitions to enhance its service offerings and market presence[200] Employee and Governance - The group has 8,169 full-time employees as of December 31, 2024, a decrease from 8,238 employees as of December 31, 2023[101] - The total employee compensation, including directors' remuneration, amounted to RMB 1,456.1 million for the year ending December 31, 2024, compared to RMB 1,335.9 million for the year ending December 31, 2023[164] - The company has established a comprehensive labor protection and compensation system to safeguard employee rights and enhance core competitiveness through a dual-channel promotion mechanism[49] Market Outlook - The private oncology medical service market in China is projected to grow at a compound annual growth rate (CAGR) of 19.8%, reaching RMB 1,092 million by 2026[56] - The overall oncology medical service market in China is expected to reach RMB 7,687 million by 2026, with a CAGR of 11.6% from 2022 to 2026[56] - Future outlook suggests a 70% target for revenue growth in the next fiscal year[200] Regulatory and Compliance - The group faces significant risks including unpredictable regulatory reforms in China's healthcare sector, which could adversely affect operations and future development[133] - The management highlighted a commitment to maintaining a 100% compliance rate with regulatory standards[200] - The group has implemented internal policies and processes for environmental protection and has complied with all relevant environmental laws and regulations during the reporting period[136] Community Engagement - The group is actively involved in community service and medical charity activities, enhancing its brand influence and social impact[45]

Investment Rating - The report assigns an "Accumulate" rating to the company [4][6]. Core Views - The company reported a revenue of 4.446 billion yuan in 2024, representing a year-on-year increase of 9.06%, while the net profit attributable to shareholders decreased by 12.40% to 598 million yuan [1][2]. - The company's gross margin for 2024 was 29.90%, down by 1.65 percentage points, with a significant decline in the second half of 2024 [2]. - The hospital business generated 4.322 billion yuan in revenue, up 11.11%, with outpatient services growing by 20.84% and inpatient services by 5.93% [3]. - The company is focusing on enhancing its oncology specialty and exploring AI integration in medical services [3]. Financial Summary - The company expects revenues of 4.885 billion yuan in 2025, 5.343 billion yuan in 2026, and 5.818 billion yuan in 2027, with corresponding net profits of 671 million yuan, 777 million yuan, and 884 million yuan respectively [4][10]. - The projected PE ratios for 2025, 2026, and 2027 are 10.66, 9.20, and 8.08 respectively [4][10]. - The company’s total assets are projected to grow from 11.850 billion yuan in 2025 to 14.030 billion yuan in 2027 [10].